Omeros announced the launch of Omidria (phenylephrine and ketorolac injection) for intraocular administration during cataract surgery and other intraocular lens (IOL) replacement procedures to prevent intraoperative miosis and to reduce postoperative ocular pain. Omidria was granted approval by the Food and Drug Administration (FDA) in June 2014.
Omidria combines phenylephrine, an alpha-1 adrenergic receptor agonist, and ketorolac, a non-steroidal anti-inflammatory. Phenylephrine acts as a mydriatic agent in the eye by contracting the radial muscle of the iris. Ketorolac inhibits both cyclooxygenase enzymes (COX-1 and COX-2), resulting in a decrease in tissue concentrations of prostaglandins to reduce pain from surgical trauma. It also prevents surgically induced miosis by inhibiting prostaglandin synthesis secondary to ocular surgical insult or direct mechanical stimulation of the iris.
Omidria is supplied as a 1%/0.3% strength in 4- and 10-count single-use 5mL vials (containing 4mL solution).
For more information call (844) OMEROS1 or visit Omidria.com.